Does TennCare Cover Wegovy & Zepbound in 2026? (New Rules)

Direct answer – TennCare and GLP-1s in 2026

Yes – as of June 2026, TennCare covers Wegovy and Zepbound for weight loss for members ages 21 and older who meet prior-authorization criteria, a major policy change that took effect August 1, 2025. TennCare requires a documented BMI of 30 or higher, or a BMI of 27 or higher with a weight-related comorbidity such as hypertension, dyslipidemia, diabetes, coronary heart disease, MASH/NASH, or obstructive sleep apnea, to approve Wegovy or Zepbound for weight loss as of June 2026. Ozempic and Mounjaro remain covered for type 2 diabetes, exactly as they were before the change.

This is a genuine before-and-after story. For years, Tennessee’s Medicaid program had a long-standing prohibition on covering obesity medications of any kind. That ended on August 1, 2025, when TennCare began covering obesity-management medications for adults 21 and older (and for members under 21 when the medication’s FDA label supports use at their age), subject to prior authorization and quantity limits, per the official TennCare/OptumRx provider notice. The change was formalized in a CMS-approved state plan amendment (TN-25-0006) and could affect more than 1.7 million TennCare enrollees, as covered by the Tennessee Lookout and the Obesity Action Coalition.

Tennessee is now one of a minority of states that cover GLP-1s for weight loss under Medicaid. To see how it stacks up against other programs, see our state-by-state Medicaid GLP-1 coverage guide, or our deep dives on MassHealth and Medi-Cal.

Important – verify your specific plan

TennCare members are enrolled through managed care organizations such as BlueCare, TennCare Select, UnitedHealthcare Community Plan, and Wellpoint, but the pharmacy benefit is administered statewide by a single pharmacy benefits manager, OptumRx. That means the GLP-1 rules described in this guide apply across TennCare regardless of which health plan card you carry. To confirm coverage for a specific medication, you or your prescriber can call the OptumRx TennCare pharmacy line at 866-434-5520 or check the TennCare pharmacy program page.

One more caution before you read on. TennCare has labeled its GLP-1 weight-management criteria as interim, and the program has already tightened the rules twice since launch. This guide reflects publicly available coverage details as of June 2026. It is educational only and is not medical or insurance advice; always confirm current criteria with TennCare or OptumRx before making treatment decisions.

TennCare GLP-1 coverage at a glance

Drug	TennCare status (2026)	Prior authorization?	Quantity limit
Wegovy (semaglutide)	Preferred for weight loss	Yes	4 injections per month
Zepbound (tirzepatide)	Preferred for weight loss	Yes	4 injections per month
Saxenda (liraglutide)	Non-preferred	Yes, plus trial of two preferred agents	Quantity limits apply
Ozempic (semaglutide)	Covered for type 2 diabetes only	Not approvable for weight loss	Per diabetes rules
Mounjaro (tirzepatide)	Covered for type 2 diabetes only	Not approvable for weight loss	Per diabetes rules
Phentermine, phentermine/topiramate, orlistat, diethylpropion, benzphetamine, phendimetrazine, Lomaira	Preferred for weight loss	No PA required	Quantity limits apply

The table reflects the August 1, 2025 obesity-management agents notice, as updated by TennCare’s December 2025 and January 2026 changes described below.

TennCare requirements for Wegovy and Zepbound

TennCare’s prior-authorization criteria for Wegovy and Zepbound are unusually specific, and they come straight from the official provider notice. To be approved, all of the following must be documented:

Obesity-management indication. The drug must be prescribed for obesity management, not off-label for another condition.
BMI threshold (adults). A documented BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related comorbidity: hypertension, dyslipidemia, diabetes, coronary heart disease, MASH/NASH, or obstructive sleep apnea.
BMI threshold (under 18, Wegovy only). A BMI at or above the 95th percentile for age and sex. Wegovy’s FDA label covers ages 12 and up; Zepbound’s label covers ages 18 and up.
Lifestyle participation. The prescriber must attest that the patient is participating in nutritional and lifestyle changes.
No combination therapy. The patient cannot combine obesity medications; only one agent is covered at a time.
Thyroid cancer screening. No personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN2).

Two more rules matter just as much as the initial checklist. Renewal requires documented weight loss of at least 5 percent of baseline body weight, and both Wegovy and Zepbound carry a quantity limit of 4 injections per month. If you are not sure whether you would clear the BMI bar, our guide on how to qualify for GLP-1 weight loss treatment walks through how BMI and comorbidity criteria work in practice.

Wegovy on TennCare (2026)

TennCare covers Wegovy for weight loss as a preferred agent with prior authorization as of June 2026. Adults need a documented BMI of 30 or higher, or 27 or higher with a qualifying comorbidity, plus the lifestyle attestation and thyroid screening described above. Wegovy is the only GLP-1 on TennCare’s weight-loss pathway with an FDA label that reaches down to age 12, so adolescents with a BMI at or above the 95th percentile for age and sex may qualify consistent with the label. Coverage is limited to 4 injections per month, and renewal depends on losing at least 5 percent of baseline weight.

Zepbound on TennCare (2026)

TennCare covers Zepbound for weight loss as a preferred agent with prior authorization as of June 2026, under the same BMI, lifestyle, and thyroid-screening criteria as Wegovy. TennCare’s obesity-medication coverage applies to adults 21 and older, with members under 21 covered consistent with the medication’s FDA label; Zepbound’s label is approved for adults 18 and older. Like Wegovy, Zepbound is limited to 4 injections per month, renewal requires documented weight loss of at least 5 percent of baseline, and only one obesity medication can be covered at a time, so members choose Wegovy or Zepbound, not both.

Ozempic on TennCare (2026)

TennCare covers Ozempic for its FDA-approved indication, type 2 diabetes, not for weight loss. That did not change in 2025; what changed is that members seeking semaglutide for weight management now have a legitimate covered route through Wegovy, which contains the same active ingredient at weight-management dosing. Note that the December 2025 rules apply across the entire GLP-1 class, so a member cannot receive Ozempic for diabetes and a weight-loss GLP-1 at the same time; TennCare pays for only one GLP-1 agent at a time.

Saxenda on TennCare – the non-preferred path

Saxenda (liraglutide), an older daily-injection GLP-1, is covered but non-preferred. TennCare will only approve it after documented trial and failure of, contraindication to, or intolerance of two preferred agents, which in practice means Wegovy and Zepbound. For most members there is little reason to start here; the weekly preferred agents are the intended first-line options, and Saxenda exists as a fallback when both of them do not work out.

The new rules since December 2025 and January 2026

TennCare did not stop adjusting the policy after launch. Effective December 12, 2025, all GLP-1 medications were placed under a drug utilization review (DUR) hard edit at the pharmacy counter, per the December 2025 provider notice. Three rules now apply:

Only one GLP-1 agent at a time will be paid for, across both diabetes and weight-management uses.
Refills are blocked until 85 percent of the days’ supply of the previous fill has elapsed.
Pharmacies are limited to a maximum of 3 overrides per rolling calendar year per member.

Then, on January 1, 2026, GLP-1 weight-management agents were formally added to TennCare’s Preferred Drug List, and initial prior-authorization approvals were set at 3 months. TennCare explicitly labels the current criteria as “interim,” which means they are evolving and could tighten or loosen again. Before starting a PA request, check the current criteria on the official TennCare pharmacy page.

Federal policy could reshape this picture again. CMS’s BALANCE Model offers states subsidized GLP-1 pricing for Medicaid weight-loss coverage, with a state opt-in deadline of July 31, 2026; Tennessee had not announced participation as of June 2026, per KFF’s analysis of the BALANCE Model. Separately, the Medicare GLP-1 Bridge will give Medicare beneficiaries access to GLP-1s at a $50 monthly copay from July 1, 2026 through December 31, 2027, per CMS, which matters for Tennesseans dually enrolled in Medicare and TennCare.

What if TennCare denies your GLP-1 prescription?

Start by finding out exactly why. Most weight-loss GLP-1 denials trace back to the checklist: a BMI that was not documented in the chart, a missing prescriber attestation about nutritional and lifestyle participation, an attempt to combine obesity medications, a thyroid-history flag, or simply an incomplete PA form. If the denial was a documentation problem, your prescriber can resubmit with complete records, and that is often the fastest fix.

If the denial stands, TennCare members have the right to appeal adverse benefit determinations through TennCare’s member appeals process; your denial letter explains how and lists the deadlines. There is also the formulary route: if you have tried and failed both Wegovy and Zepbound, or cannot take them, the non-preferred Saxenda pathway opens up.

Renewal denials are their own category. TennCare requires documented weight loss of at least 5 percent of baseline to reauthorize Wegovy or Zepbound, so a renewal can be denied even after a clean initial approval. If you are short of the 5 percent mark, talk to your prescriber about your documentation, your options within TennCare’s rules, and whether a different covered agent makes sense.

GLP-1 alternatives for TennCare members in 2026

Not everyone fits TennCare’s criteria. You might have a BMI between 25 and 27 with no qualifying comorbidity, lose coverage at renewal under the 5 percent rule, run into the one-agent or 3-month reauthorization friction, or simply prefer not to route a weight-loss prescription through Medicaid. Cash-pay telehealth programs are the main alternative, and you can compare the leading weight-loss telehealth providers here.

Ro Body Program

Ro’s Body Program pairs GLP-1 prescriptions (where clinically appropriate) with provider oversight, insurance-paperwork support, and ongoing coaching. For TennCare members, Ro is most relevant if you do not meet the program’s PA criteria or want a cash-pay route that is not subject to TennCare’s interim rules. See Ro Body Program pricing. Read our full Ro review for every plan and price.

Remedy Meds

Remedy Meds is a telehealth weight-loss program built around straightforward cash pricing, with no insurance or prior authorization involved. That makes it a common fallback for people whose Medicaid PA was denied or not renewed. See Remedy Meds pricing. Our full Remedy Meds review covers the program in detail.

Trim Rx

Trim Rx is a cash-pay compounded telehealth program with flat published pricing – oral semaglutide from $179/month and tirzepatide at $349/month flat at every dose, as of June 2026 – with no insurance or prior authorization involved. It is a young company (founded 2024), so see our Trim Rx review for the complaint patterns and billing terms before you commit.

How to apply for prior authorization

You cannot submit a TennCare PA yourself; your prescriber handles it through OptumRx. Here is how the process works in practice:

See your prescriber and get the chart right. Your BMI must be documented, along with any qualifying comorbidity (hypertension, dyslipidemia, diabetes, coronary heart disease, MASH/NASH, or obstructive sleep apnea) if your BMI is between 27 and 30.
Document lifestyle participation. The PA requires the prescriber to attest that you are participating in nutritional and lifestyle changes, so make sure that work is reflected in your record.
Screen for exclusions. Confirm there is no personal or family history of medullary thyroid carcinoma or MEN2, and that you are not taking another obesity medication.
Submit the form. Your prescriber completes TennCare’s Obesity Management Agents PA form and submits it through OptumRx, TennCare’s pharmacy benefits manager.
Track the decision and the clock. Initial approvals run 3 months as of January 1, 2026, and renewal will require documented weight loss of at least 5 percent of baseline. You or your prescriber can check PA status via the OptumRx line at 866-434-5520.

Frequently asked questions

Does TennCare cover Wegovy for weight loss?

Yes. As of June 2026, TennCare covers Wegovy for weight loss as a preferred agent with prior authorization, a policy that took effect August 1, 2025. Adults need a documented BMI of 30 or higher, or 27 or higher with a weight-related comorbidity, plus a prescriber attestation of nutritional and lifestyle participation. Coverage is limited to 4 injections per month.

What are TennCare’s requirements for Zepbound?

TennCare approves Zepbound for weight loss when the prescription is for obesity management, the adult patient has a documented BMI of 30 or higher (or 27 or higher with hypertension, dyslipidemia, diabetes, coronary heart disease, MASH/NASH, or obstructive sleep apnea), the prescriber attests to nutritional and lifestyle participation, no other obesity medication is being used, and there is no personal or family history of medullary thyroid carcinoma or MEN2. Renewal requires documented weight loss of at least 5 percent of baseline.

Does TennCare cover Ozempic?

Yes, for type 2 diabetes, which is its FDA-approved indication. TennCare does not approve Ozempic for weight loss; members seeking semaglutide for weight management would go through the Wegovy pathway instead. Under the December 2025 rules, TennCare pays for only one GLP-1 agent at a time.

How long does a TennCare GLP-1 approval last?

As of January 1, 2026, initial prior-authorization approvals for GLP-1 weight-management agents run 3 months. Continued coverage after that requires a renewal request showing documented weight loss of at least 5 percent of baseline body weight.

Does TennCare cover Saxenda?

Yes, but as a non-preferred agent. TennCare requires documented trial and failure of, contraindication to, or intolerance of two preferred agents (Wegovy and Zepbound) before it will approve Saxenda for weight loss.

What if I’m under 21?

TennCare’s obesity-medication coverage applies to adults 21 and older, with members under 21 covered consistent with the medication’s FDA label. Wegovy is labeled for ages 12 and up, and members under 18 must have a BMI at or above the 95th percentile for age and sex. Zepbound’s label covers adults 18 and older. Ask your prescriber to confirm how the label-based rule applies to your age.

What happens at renewal if I haven’t lost 5% of my weight?

TennCare’s renewal criterion requires documented weight loss of at least 5 percent of baseline, so if that threshold is not met, the reauthorization request does not satisfy the published criteria and coverage may not be renewed. Talk to your prescriber about your documentation and options, which can include a different covered agent or cash-pay telehealth programs outside TennCare.

Does TennCare Cover GLP-1 Weight Loss Drugs in 2026?